NEW YORK (GenomeWeb) – Having completed the first phase of a $1 million National Cancer Institute grant to develop a panel of tumor-associated antibodies (TAAs) to help detect cancer and assess patient response to immune-modulating cancer drugs, Genalyte is now gearing up to manufacture a set of chips covering this panel to support the second phase of the project.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.